Evidence map›Paper›PMID 41477350›Full record

ReviewActa pharmaceutica Sinica. B2025

Recent advances in engineering nano/microrobots for tumor treatment.

Xifeng Qin, Ruizhe Xu, Jiayi Wu, Yue Liu, Ting Wang, Hongyan Tu, Jia Li, Zhiqing Pang

Abstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Performance Estimation and Ex Vivo Validation of Untethered Magnetic Robots in Soft Tissue.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xifeng QinSchool of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.
Ruizhe XuSchool of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.
Jiayi WuSchool of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.
Yue LiuSchool of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.
Ting WangSchool of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.
Hongyan TuSchool of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.
Jia LiDepartment of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney NSW 2109, Australia.
Zhiqing PangSchool of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Until now, although nanomedicines have gained much success in tumor treatment by reducing severe toxic side effects of drugs and improving the therapeutic efficiency of drugs, they are still faced with thorny challenges in targeted drug delivery including insufficient targeting accuracy, poor penetration into tumor core, and systemic toxicity issues. Recently, engineering nano/microrobots with multiple remarkable properties such as real-time sensing, interacting and manipulating capabilities, and programmability, have received increasing attention in biomedical applications ranging from disease diagnosis, targeted drug delivery, medical imaging, and surgery. More importantly, in different driven modes, nano/microrobots are capable of performing a wide variety of powerful functions, such as enhancing tissue penetration and payload retention in deep-seated tumors with active navigation, being programmable to release drugs or performing specific tasks directly at the tumor site with high precision and accuracy, automating repeated tumor treatment without the need for frequent interventions, and minimizing out-of-target tissue damage, leading to a huge exploration potential in tumor treatment. In this review, we delve into the recent progress and the development direction of nano/microrobots for tumor treatment and emphasize the working mechanisms and the unique functionalities of different driven modes in detail. Meanwhile, we elaborate on the application of nano/microrobots fabricated from various types of materials in tumor therapy. Finally, the key factors to be considered in the clinical translation of the above nano/microrobots are proposed.

Indexed as

Autonomous navigationBiocompatibilityBiomedical applicationsDriven modeDrug deliveryNano/microrobotsTargeted therapyTumor treatment

Identifiers

PMID41477350
PMCPMC12750171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.